JP2016512203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512203A5 JP2016512203A5 JP2015561914A JP2015561914A JP2016512203A5 JP 2016512203 A5 JP2016512203 A5 JP 2016512203A5 JP 2015561914 A JP2015561914 A JP 2015561914A JP 2015561914 A JP2015561914 A JP 2015561914A JP 2016512203 A5 JP2016512203 A5 JP 2016512203A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 14
- -1 aralkenyl Chemical group 0.000 claims description 11
- BQEUECRVCKCNDI-UHFFFAOYSA-N 4-[4-(2-fluoro-5-methylphenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound CC1=CC=C(F)C(C2(O)CCN(CC2)C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)=C1 BQEUECRVCKCNDI-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 8
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- BFBYUBBUQICKBI-UHFFFAOYSA-N 4-[4-hydroxy-4-(4-methylphenyl)piperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1(O)CCN(C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)CC1 BFBYUBBUQICKBI-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 208000007475 hemolytic anemia Diseases 0.000 claims description 5
- FKIRFDIHZTZLHM-UHFFFAOYSA-N 4-[4-(3-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=C(F)C=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 FKIRFDIHZTZLHM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 claims description 2
- VKTRIIOQTOLRAS-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 VKTRIIOQTOLRAS-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- BAJLNYHQTYVIOS-UHFFFAOYSA-N methyl 1-[4-[(2-methylphenyl)sulfamoyl]benzoyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1C BAJLNYHQTYVIOS-UHFFFAOYSA-N 0.000 claims description 2
- WXRMODUITVDKEN-UHFFFAOYSA-N methyl 4-phenyl-1-[4-(phenylsulfamoyl)benzoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1 WXRMODUITVDKEN-UHFFFAOYSA-N 0.000 claims description 2
- AUWWKKUWIICCOE-UHFFFAOYSA-N n-(4-fluorophenyl)-4-[4-hydroxy-4-(methoxymethyl)piperidine-1-carbonyl]benzenesulfonamide Chemical compound C1CC(COC)(O)CCN1C(=O)C1=CC=C(S(=O)(=O)NC=2C=CC(F)=CC=2)C=C1 AUWWKKUWIICCOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims 4
- 208000022806 beta-thalassemia major Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims 2
- 208000035623 congenital anemia Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000009601 hereditary spherocytosis Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 4
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DWOBOHJJJHTHGQ-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nc(N)[s]c2ccc1)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nc(N)[s]c2ccc1)(=O)=O)=O)O DWOBOHJJJHTHGQ-UHFFFAOYSA-N 0.000 description 1
- JTGUGSWLWPKCGF-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nccnc2ccc1)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nccnc2ccc1)(=O)=O)=O)O JTGUGSWLWPKCGF-UHFFFAOYSA-N 0.000 description 1
- PNHFJXKSMARJSQ-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1cccc2c1ncnc2O)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1cccc2c1ncnc2O)(=O)=O)=O)O PNHFJXKSMARJSQ-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072688 | 2013-03-15 | ||
| PCT/CN2013/072688 WO2014139144A1 (en) | 2013-03-15 | 2013-03-15 | Therapeutic compounds and compositions |
| PCT/CN2014/000260 WO2014139325A1 (en) | 2013-03-15 | 2014-03-13 | Therapeutic compounds and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042775A Division JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512203A JP2016512203A (ja) | 2016-04-25 |
| JP2016512203A5 true JP2016512203A5 (enExample) | 2017-04-13 |
| JP6374413B2 JP6374413B2 (ja) | 2018-08-15 |
Family
ID=51535825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561914A Expired - Fee Related JP6374413B2 (ja) | 2013-03-15 | 2014-03-13 | 治療化合物および組成物 |
| JP2017042775A Withdrawn JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042775A Withdrawn JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160046579A1 (enExample) |
| EP (1) | EP2970189B1 (enExample) |
| JP (2) | JP6374413B2 (enExample) |
| CN (1) | CN105121425A (enExample) |
| AR (1) | AR095557A1 (enExample) |
| AU (1) | AU2014231564B2 (enExample) |
| BR (1) | BR112015023760A2 (enExample) |
| CA (1) | CA2903067A1 (enExample) |
| CL (1) | CL2015002767A1 (enExample) |
| CR (1) | CR20150571A (enExample) |
| ES (1) | ES2803548T3 (enExample) |
| HK (1) | HK1216175A1 (enExample) |
| IL (1) | IL241352A0 (enExample) |
| MX (1) | MX2015012882A (enExample) |
| NI (1) | NI201500140A (enExample) |
| PE (1) | PE20151793A1 (enExample) |
| PH (1) | PH12015502161A1 (enExample) |
| RU (1) | RU2015143908A (enExample) |
| SG (1) | SG11201507332SA (enExample) |
| TW (1) | TW201444797A (enExample) |
| WO (2) | WO2014139144A1 (enExample) |
| ZA (1) | ZA201506487B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EA037299B1 (ru) | 2014-09-17 | 2021-03-05 | Селджен Кар Ллс | Ингибиторы mk2 и их применения |
| CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| PL3386591T3 (pl) | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| CN107298685A (zh) * | 2017-06-29 | 2017-10-27 | 上海合全药业股份有限公司 | 一种8‑(叔丁氧羰基)‑1‑氧杂‑8‑氮杂螺[4.5]癸烷‑2‑羧酸的合成方法 |
| SG11202001262QA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in treating blood disorders |
| DK3700902T3 (en) | 2017-10-27 | 2023-05-22 | Boehringer Ingelheim Int | Inhibitorer af trpc6 |
| ES2987073T3 (es) | 2018-08-02 | 2024-11-13 | Dev Ct Biotechnology | Proceso regioselectivo de un solo paso para sintetizar 2-hidroxiquinoxalina |
| RS64359B1 (sr) | 2018-08-03 | 2023-08-31 | Novartis Ag | Heteroaromatični modulatori nmda receptora i njihove upotrebe |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| KR102779909B1 (ko) * | 2018-12-18 | 2025-03-12 | 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 | 이소퀴놀린술포닐클로라이드 산부가염 및 그 제조 방법 |
| WO2021029450A1 (ko) * | 2019-08-09 | 2021-02-18 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| CN112773800B (zh) * | 2021-01-25 | 2021-10-15 | 南通大学 | 哌啶-1-二硫代甲酸-3-甲基-1，4-二氧-1，4-二氢萘-2-甲基酯的用途 |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN117337292A (zh) | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| IL307790A (en) * | 2021-05-12 | 2023-12-01 | Boehringer Ingelheim Int | Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors |
| TWI841134B (zh) | 2021-12-21 | 2024-05-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 含二氮雜亞基磺醯結構的化合物及其在醫藥上的用途 |
| CN115073422A (zh) * | 2022-07-28 | 2022-09-20 | 成都普瑞熙药业有限公司 | 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法 |
| ES2975743A1 (es) * | 2022-11-22 | 2024-07-12 | Moehs Iberica Sl | Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos |
| KR20260014544A (ko) | 2023-05-26 | 2026-01-30 | 시노허브 파마슈티컬 씨오., 엘티디 | 빈혈 관련 질환의 치료에 있어서 비스(아자니릴리덴) 설포닐 구조 화합물을 함유하는 약학적 조성물의 용도 |
| WO2025191185A1 (en) * | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
| WO2025233901A1 (en) | 2024-05-09 | 2025-11-13 | Biohaven Therapeutics Ltd. | Activators of pyruvate kinase isoform m2 and methods for treating neurodegenerative disease |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL76414C (enExample) | 1949-07-23 | |||
| GB935538A (en) | 1959-04-06 | 1963-08-28 | Stop Motion Devices Corp | Stop-motion head for use on knitting machines |
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| GB8325370D0 (en) | 1983-09-22 | 1983-10-26 | Fujisawa Pharmaceutical Co | Benzoxazoline and benzothiazoline derivatives |
| JPS61129129A (ja) | 1984-11-28 | 1986-06-17 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| FI855180A7 (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyratsolisulfonamidijohdannainen, menetelmä sen valmistamiseksi ja sitä sisältävä rikkaruohomyrkky. |
| EP0246749A3 (en) | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
| JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
| US4775762A (en) | 1987-05-11 | 1988-10-04 | The Dow Chemical Company | Novel (1H-1,2,3-triazol-1-yl)pyridines |
| DE3813886A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| DE3813885A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| US5220028A (en) | 1988-10-27 | 1993-06-15 | Nissan Chemical Industries, Ltd. | Halogeno-4-methylpyrazoles |
| MY106533A (en) | 1990-02-20 | 1995-06-30 | Sumitomo Chemical Co | A 4-tert.-butyl imidazole derivative and its production and use. |
| CA2036147A1 (en) | 1990-06-29 | 1991-12-30 | Hiroki Tomioka | A 1-pyridylimidazole derivative and its production and use |
| DK0565593T3 (da) | 1990-12-31 | 1999-09-27 | Monsanto Co | Reducering af pesticidinteraktion i afgrøder |
| AU644297B2 (en) | 1991-06-28 | 1993-12-02 | Sumitomo Chemical Company, Limited | A 1-pyridylimidazole derivative and its production and use |
| JPH0625177A (ja) | 1992-07-09 | 1994-02-01 | Nissan Chem Ind Ltd | ピラゾール誘導体及び除草剤 |
| JP3719612B2 (ja) | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
| DE19541146A1 (de) | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| AU725548B2 (en) | 1997-03-11 | 2000-10-12 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| EP1109544A4 (en) | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
| JP2002527359A (ja) | 1998-09-18 | 2002-08-27 | ビーエーエスエフ アクチェンゲゼルシャフト | キナーゼインヒビターとしての４−アミノピロリピリミジン |
| US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| BR0013694A (pt) | 1999-09-04 | 2002-05-21 | Astrazeneca Ab | Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto |
| JP2002193710A (ja) | 2000-12-25 | 2002-07-10 | Kumiai Chem Ind Co Ltd | ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤 |
| JP2004529164A (ja) | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| ATE396985T1 (de) | 2001-08-15 | 2008-06-15 | Du Pont | Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| AU2002361577A1 (en) | 2001-10-30 | 2003-05-12 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| WO2003062235A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| MXPA04007775A (es) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa. |
| JP4901102B2 (ja) | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| GB0215775D0 (en) | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| ATE482938T1 (de) | 2002-08-09 | 2010-10-15 | Merck Sharp & Dohme | Tyrosinkinaseinhibitoren |
| KR20050059294A (ko) | 2002-10-24 | 2005-06-17 | 스테릭스 리미티드 | 11-베타-하이드록시 스테로이드 데하이드로게나제 형태 1및 형태 2의 억제제 |
| AU2003300902A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| EP1618090A1 (en) * | 2003-04-11 | 2006-01-25 | Novo Nordisk A/S | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| CA2528003A1 (en) | 2003-06-10 | 2004-12-23 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| US6818631B1 (en) | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| EP1797076A1 (en) | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| EP1812008A4 (en) | 2004-10-20 | 2008-10-29 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| SE0402762D0 (sv) | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| US8076370B2 (en) | 2005-05-03 | 2011-12-13 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| EP1910321A4 (en) | 2005-07-05 | 2010-09-01 | Astrazeneca Ab | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE |
| US20080214495A1 (en) | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| AR056682A1 (es) | 2005-07-29 | 2007-10-17 | Kalypsys Inc | COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA |
| CA2618370A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| JP2007238458A (ja) | 2006-03-06 | 2007-09-20 | D Western Therapeutics Institute Inc | 新規なイソキノリン誘導体及びこれを含有する医薬 |
| WO2007108742A1 (en) | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel tetralins as 5-ht6 modulators |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| CN101437519A (zh) | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| WO2008019139A2 (en) | 2006-08-04 | 2008-02-14 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| EP2056828A4 (en) | 2006-08-21 | 2010-06-23 | Merck Sharp & Dohme | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS |
| KR101428681B1 (ko) | 2006-09-01 | 2014-08-11 | 오에이티 아그리오 가부시키가이샤 | Ｎ―피리딜피페리딘 화합물, 그의 제조 방법 및 유해 생물 방제제 |
| EP2527345B1 (en) | 2006-10-16 | 2015-12-16 | Thesan Pharmaceuticals, Inc. | Therapeutic pyrazolyl thienopyridines |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| JP5361857B2 (ja) * | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| AR067602A1 (es) | 2007-07-18 | 2009-10-14 | Janssen Pharmaceutica Nv | Sulfonamida como moduladores del trpm8 |
| JP2011500750A (ja) | 2007-10-26 | 2011-01-06 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 新規イミダゾール誘導体 |
| EP2053045A1 (en) | 2007-10-26 | 2009-04-29 | Syngenta Participations AG | Novel imidazole derivatives |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2732791A1 (en) * | 2008-08-05 | 2010-02-11 | Targegen, Inc. | Methods of treating thalassemia |
| CA2771226A1 (en) * | 2008-08-22 | 2010-02-25 | James Madden | New bradykinin b1 antagonists |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| JP5632379B2 (ja) | 2008-10-09 | 2014-11-26 | アメリカ合衆国 | ヒトピルビン酸キナーゼ活性化剤 |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| CA2759547A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| DK2427441T3 (en) | 2009-05-04 | 2017-03-20 | Agios Pharmaceuticals Inc | PKM2 Activators for use in the treatment of cancer |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| CR20170071A (es) * | 2009-06-29 | 2017-03-28 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones |
| EP2528893B1 (en) | 2010-01-29 | 2018-10-10 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| KR20130044382A (ko) | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | 화합물 및 그의 치료 용도 |
| CA2797694A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| EP2651898B1 (en) * | 2010-12-17 | 2015-12-09 | Agios Pharmaceuticals, Inc. | Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| CA2834692A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| CN102805860A (zh) * | 2011-05-30 | 2012-12-05 | 复旦大学 | 丙酮酸激酶2乙酰化抑制剂及其用途 |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2013
- 2013-03-15 WO PCT/CN2013/072688 patent/WO2014139144A1/en not_active Ceased
-
2014
- 2014-03-13 US US14/776,635 patent/US20160046579A1/en not_active Abandoned
- 2014-03-13 EP EP14765650.8A patent/EP2970189B1/en active Active
- 2014-03-13 AU AU2014231564A patent/AU2014231564B2/en not_active Ceased
- 2014-03-13 CA CA2903067A patent/CA2903067A1/en not_active Abandoned
- 2014-03-13 JP JP2015561914A patent/JP6374413B2/ja not_active Expired - Fee Related
- 2014-03-13 HK HK16104168.0A patent/HK1216175A1/zh unknown
- 2014-03-13 BR BR112015023760A patent/BR112015023760A2/pt not_active IP Right Cessation
- 2014-03-13 PE PE2015002010A patent/PE20151793A1/es not_active Application Discontinuation
- 2014-03-13 RU RU2015143908A patent/RU2015143908A/ru not_active Application Discontinuation
- 2014-03-13 SG SG11201507332SA patent/SG11201507332SA/en unknown
- 2014-03-13 CN CN201480021459.8A patent/CN105121425A/zh active Pending
- 2014-03-13 MX MX2015012882A patent/MX2015012882A/es unknown
- 2014-03-13 WO PCT/CN2014/000260 patent/WO2014139325A1/en not_active Ceased
- 2014-03-13 ES ES14765650T patent/ES2803548T3/es active Active
- 2014-03-14 US US14/210,583 patent/US9108921B2/en active Active
- 2014-03-14 TW TW103109338A patent/TW201444797A/zh unknown
- 2014-03-17 AR ARP140101179A patent/AR095557A1/es unknown
-
2015
- 2015-07-31 US US14/814,862 patent/US9365545B2/en active Active
- 2015-09-03 ZA ZA2015/06487A patent/ZA201506487B/en unknown
- 2015-09-09 IL IL241352A patent/IL241352A0/en unknown
- 2015-09-15 PH PH12015502161A patent/PH12015502161A1/en unknown
- 2015-09-15 CL CL2015002767A patent/CL2015002767A1/es unknown
- 2015-09-16 NI NI201500140A patent/NI201500140A/es unknown
- 2015-10-15 CR CR20150571A patent/CR20150571A/es unknown
-
2017
- 2017-03-07 JP JP2017042775A patent/JP2017105832A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512203A5 (enExample) | ||
| RU2015143908A (ru) | Терапевтические соединения и композиции | |
| JP2016501189A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| EA202190086A1 (ru) | Соединения-антагонисты pcsk9 | |
| JP2019507179A5 (enExample) | ||
| JP2008110984A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2014511869A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2017510555A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2019519616A5 (enExample) | ||
| JP2017509694A5 (enExample) | ||
| RU2011144763A (ru) | 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины | |
| JP2016503797A5 (enExample) | ||
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2019501130A5 (enExample) |